Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology

Launched by UNIVERSITY HOSPITAL, CAEN · Feb 12, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how Staphylococcus aureus, specifically a type known as MSSA, affects newborns in the Neonatal Intensive Care Unit (NICU). Newborns in the NICU are at higher risk for infections, and MSSA can lead to serious complications like sepsis, which can make them sicker and prolong their hospital stay. The study aims to track how MSSA spreads between patients, how often newborns carry this bacteria, and how effective treatments are in getting rid of it.

To participate in this trial, newborns who are currently hospitalized in the NICU and are known to be carriers of MSSA may be eligible. There are no exclusions based on other factors, meaning if your baby meets the basic criteria, they can be considered for the study. If enrolled, participants will be part of a program that monitors their health regarding MSSA, helping doctors learn more about how to manage and prevent these infections in vulnerable newborns.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • newborns hospitalized in neonatal ICU
• • MSSA carrier
• Exclusion Criteria:
• • none